Increase of lipid plasma concentrations under protease inhibitor-containing regimens are not related to modifications of the tumour necrosis factor system.
Bonnet
F
F
Savès
M
M
Droz
C
C
Peuchant
E
E
Chêne
G
G
Beylot
J
J
Morlat
P
P
D000328:Adult; D015703:Antigens, CD / Q000097:blood*; D002784:Cholesterol / Q000097:blood*; D005260:Female; D005500:Follow-Up Studies; D015658:HIV Infections / Q000097:blood* / Q000188:drug therapy; D017320:HIV Protease Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D015497:HIV-1 / Q000235:genetics; D006801:Humans; D008297:Male; D011446:Prospective Studies; D018124:Receptors, Tumor Necrosis Factor / Q000097:blood*; D047889:Receptors, Tumor Necrosis Factor, Type II; D014280:Triglycerides / Q000097:blood*
D015703:Antigens, CD; D017320:HIV Protease Inhibitors; D018124:Receptors, Tumor Necrosis Factor; D047889:Receptors, Tumor Necrosis Factor, Type II; D014280:Triglycerides; D002784:Cholesterol